CMI Explores Emerging Lyme Disease Diagnostics Market Trends and Broad Scope By 2027
“The Lyme Disease Diagnostics Market 2021 – 2027 report covers the important factors driving the growth of the market, untapped opportunities for manufacturers, trends and developments shaping the dynamics of the market and other insights across various key segments.”
The Lyme Disease Diagnostics research report covers the current scenario and the growth prospects of the global Lyme Disease Diagnostics industry forecast 2021 – 2027. The report enlists several important factors, starting from the basics principal to advanced market intelligence which play a vital part in strategizing. Lyme Disease Diagnostics manufacturers and is a important source of guidance and direction for companies and individuals interested in the Lyme Disease Diagnostics industry.
The bacterium Borrelia burgdorferi (Bb) causes Lyme disease, which is transmitted to humans through the bite of infected blacklegged ticks. Fatigue, headache, fever, and an erythema migrans-like skin rash are all common symptoms. If left unchecked, the bacteria can affect the heart, the neurological system, and joints. There is no need for further testing if the initial screening phase is negative. The second screening phase, a Western blot test, is conducted if the first screening step is positive or not clear. Only if both screening tests are positive are the results deemed positive. The CDC advises against skipping the first screening stage since it will increase the likelihood of false positive results.
Lyme disease is a challenging medical illness to diagnose because of the growing number of tick-borne infectious diseases, the introduction of novel vector-borne diseases, and the complexity and variability of indications in each patient. Over the forecast period, the global Lyme disease diagnostics market is projected to rise due to increasing Lyme disease prevalence and increased government focus on improving healthcare facilities. According to a 2016 estimate from the National Institute of Allergy and Infectious Diseases (NIAID), over 300,000 cases of Lyme disease are recorded each year in the United States alone. NIAID, among other government agencies and institutes, is striving to improve Lyme disease diagnosis. The National Institute of Allergy and Infectious Diseases actively funds research on Lyme disease diagnosis. In conjunction with the CDC, the National Institute of Allergy and Infectious Diseases encourages the development of innovative approaches to enhance Lyme disease screening in patients who have co-illnesses such as tick-borne infections.
Furthermore, manufacturers are concentrating on the research and development of novel Lyme disease diagnostic tests, which is anticipated to help the global Lyme disease diagnostics market expand. In 2017, IGeneX Inc., a CLIA- and New York-approved Reference Laboratory specialized in tick-borne illness testing, released three new procedures that are more thorough and specific for aiding in the identification of tick-borne relapsing fever and Lyme disease.
The global Lyme disease diagnostics market’s expansion is hampered by the lack of knowledge of the condition and ineffective Lyme disease testing. Since present serological tests can’t detect antibodies to all of the various strains of B. burgdorferi, several people with Lyme-like symptoms are misdiagnosed.
During the forecast period, the North American Lyme disease diagnostics market is projected to maintain its dominance. This is attributable to an increase in government programs for illness diagnosis and treatment. The Centers for Disease Control and Prevention has intensified its attention on developing innovative Lyme disease prevention techniques in order to minimize illness incidence in specific populations.
Another factor driving market expansion in the region is the rising prevalence of common tick illness, which has resulted in a high demand for effective disease treatment. Lyme disease is the most common tick-borne infection in North America and Europe, according to a study. It is currently the most often reported vector-borne illness in the U.S. According to the Centers for Disease Control and Prevention, it was the nation’s sixth most frequent Nationally Notifiable Disease in 2015. Due to an increase in the number of infected patients in Europe, the market for Lyme disease diagnostics is projected to develop rapidly. In several European nations, the prevalence of Lyme disease has been steadily rising.
Major Key Players Include In Lyme Disease Diagnostics Market: Abbott Laboratories, Affymetrix Inc., Alere Inc., Baxter International Inc., Bio-Rad Laboratories, Boulder Diagnostics, Canon Life Sciences, Covance Inc., Fresenius Medical Care AG & Co., GlaxoSmithKline Pharmaceuticals Ltd., Roche Diagnostics International Ltd., Siemens AG, and T2 Biosystems, Immunetics Inc.
“Limited Time Offer”
Get This premium report with Instant US$ 2000 discount @ https://www.coherentmarketinsights.com/promo/buynow/1608
Main points in Lyme Disease Diagnostics Market Report Table of Content
Chapter 1 Industry Overview
1.3 Research Scope
1.4 Market Analysis by Regions
1.5 Lyme Disease Diagnostics Market Size Analysis from 2021 to 2027
11.6 COVID-19 Outbreak: Lyme Disease Diagnostics Industry Impact
Chapter 2 Global Lyme Disease Diagnostics Competition by Types, Applications, and Top Regions and Countries
2.1 Global Lyme Disease Diagnostics (Volume and Value) by Type
2.3 Global Lyme Disease Diagnostics (Volume and Value) by Regions
Chapter 3 Production Market Analysis
3.1 Global Production Market Analysis
3.2 Regional Production Market Analysis
Chapter 4 Global Lyme Disease Diagnostics Sales, Consumption, Export, Import by Regions (2016-2021)
Chapter 5 North America Lyme Disease Diagnostics Market Analysis
Chapter 6 East Asia Lyme Disease Diagnostics Market Analysis
Chapter 7 Europe Lyme Disease Diagnostics Market Analysis
Chapter 8 South Asia Lyme Disease Diagnostics Market Analysis
Chapter 9 Southeast Asia Lyme Disease Diagnostics Market Analysis
Chapter 10 Middle East Lyme Disease Diagnostics Market Analysis
Chapter 11 Africa Lyme Disease Diagnostics Market Analysis
Chapter 12 Oceania Lyme Disease Diagnostics Market Analysis
Chapter 13 South America Lyme Disease Diagnostics Market Analysis
Chapter 14 Company Profiles and Key Figures in Lyme Disease Diagnostics Business
Chapter 15 Global Lyme Disease Diagnostics Market Forecast (2021-2027)
Chapter 16 Conclusions
Coherent Market Insights is a global market intelligence and consulting organization focused on assisting our plethora of clients to achieve transformational growth by helping them make critical business decisions. We are headquartered in India, having an office at global financial capital in the U.S. and sales consultants in the United Kingdom and Japan. Our client base includes players from across various business verticals in over 150 countries worldwide. We pride ourselves in catering to clients across the length and width of the horizon, from Fortune 500 enlisted companies to not-for-profit organizations, and startups looking to establish a foothold in the market. We excel in offering unmatched actionable market intelligence across various industry verticals, including chemicals and materials, healthcare, and food & beverages, consumer goods, packaging, semiconductors, software and services, Telecom, and Automotive. We offer syndicated market intelligence reports, customized research solutions, and consulting services.
Coherent Market Insights
1001 4th Ave, #3200
Seattle, WA 98154
Phone: US +12067016702 / UK +4402081334027
- CDN Newswire